Evidence & regulatory context
- Mechanism
- Uric acid oxidative enzyme (OXIDATIVE ENZYME)
- Target
- CHEMBL2364183
- Injury models
- Haemorrhage/shock
- Reported indication
- Not recorded
- First approval
- 2001
- Development stage
- Not recorded
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Rasburicase; Elitek; Fasturtec; Rasuritek; SR-29142; Urate oxidase
- Note
- Not recorded
Clinical trials 10
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy
Childhood Burkitt Lymphoma · Childhood Diffuse Large Cell Lymphoma · Untreated Childhood Acute Lymphoblastic Leukemia
Enrolment: 97 · Results not recorded
Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome
Hyperuricemia
Enrolment: 33 · Results not recorded
Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease
Tumors · Hyperuricemia · Tumor Lysis Syndrome
Enrolment: 94 · Results not recorded
A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylaxis for Tumor Lysis Syndrome
Tumor Lysis Syndrome
Enrolment: 45 · Results not recorded
Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia
Hyperuricemia
Enrolment: 100 · Results not recorded
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Tolerance, Pharmacokinetics/Pharmacodynamics and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers
Hyperuricemia
Enrolment: 54 · Results not recorded
A Phase I Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
Hyperuricemia · Gout
Enrolment: 18 · Results not recorded
A Phase 1, Single Centre, Two-Part, Open Label, Crossover Study in Healthy Volunteers Using Scintigraphy to Characterize the In Vivo Performance of ALLN-346 Enteric Coated Tablets
Hyperuricemia · Gout
Enrolment: 12 · Results not recorded
A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies
Leukemia · Lymphoma · Tumor Lysis Syndrome · Hyperuricemia
Enrolment: 16 · Results not recorded
A Multicenter Registry Study of Anti-rasburicase Antibodies in Patients Retreated With Rasburicase (SR29142) in the Context of Relapsing Leukemia/Lymphoma Who Experienced Subsequent Hypersensitivity Reaction(s) or Loss of Uricolytic Activity
Tumor Lysis Syndrome
Enrolment: 1 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatHaemorrhage/shockUnspecifiedWistarMaleAdministered during resuscitationDuring resuscitation after haemorrhagic shock
Model: Resuscitated haemorrhagic shock with ischaemia-reperfusion, treatment given during resuscitation
Uricase added to resuscitation lowered circulating and hepatic uric acid and prevented hepatolysis, hepatic apoptotic and inflammatory mediator rises at 24 and 72 hours, and prevented shock-induced enteric hyperpermeability and endotoxaemia.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
